LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Solid Biosciences stock or options Pursuant to the Company’s Initial Public Offering on January 25, 2018 and/or between January 25, 2018, and March 14, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/SLDB.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who acquired common stock of Solid Biosciences pursuant to the Company’s IPO on January 25, 2018 and/or between January 25, 2018, and March 14, 2018 (the “Class Period”).  The case, Watkins v. Solid Biosciences, Inc. et al, No. 1:18-cv-10587 was filed on March 27, 2018 and has been assigned to Judge Mark Lawrence Wolf.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose: (1) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, the Company’s statements in the Registration Statement regarding its business, operations, and prospects, were materially false and/or misleading.

On January 30, 2018, an article was published by various medical experts highlighting the risks of studies using high doses of gene therapies using adeno-associated virus (AAV).

Following this publication, Solid Biosciences’ share price fell from $23.70 per share on January 29, 2018 to a closing price of $22.50 on January 30, 2018 —a $1.20 or a 5.06% drop.

On March 14, 2018, after the close of trading, the Company published a press release announcing that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the SGT-001 Phase I/II clinical trial, IGNITE DMD.

After the announcement, Solid Biosciences’ share price fell from $26.31 per share on March 14, 2018 to a closing price of $9.32 on March 15, 2018 —a $16.99 or a 64.58% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Solid Biosciences’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.